• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

    9/17/21 3:04:41 PM ET
    $CERC
    Major Pharmaceuticals
    Health Care
    Get the next $CERC alert in real time by email
    SC 13D/A 1 sc_13da_avalo.htm

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, DC 20549
     
    SCHEDULE 13D
    THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 19)*
     
     
    Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.)
    (Name of Issuer)
     
     
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)
     
     
    05338F108
    (CUSIP Number)
     
     
    Brian Kohn
    c/o Armistice Capital, LLC
    510 Madison Avenue
    7th Floor
    New York, NY 10022
    Telephone Number: (212) 231-4930
    (Name, Address and Telephone Number of Person Authorized to Receive
    Notices and Communications)
     
     
    September 17, 2021
    (Date of Event Which Requires Filing of this Statement)
     
     
    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box [  ].
     
     
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
     


     
     


     
    CUSIP No. 05338F108
    1
    NAMES OF REPORTING PERSONS
     
     

    Armistice Capital, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     

    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    49,000,000
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    49,000,000
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    49,000,000
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    43.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IA, OO
     
     
     
     
     





    CUSIP No. 05338F108
    1
    NAMES OF REPORTING PERSONS
     
     

    Steven Boyd
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     

    AF
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
     
    412,442
     
     
     
     
    8
    SHARED VOTING POWER
     
     
     
    49,000,000
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
     
    412,442
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
     
    49,000,000
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     
    412,442
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
     
    43.9%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     
    IN, HC
     
     
     








    Amendment No. 19 to Schedule 13D

    The following constitutes Amendment No. 19 to the Schedule 13D filed by the undersigned (“Amendment No. 19”).  This Amendment No. 19 amends the Schedule 13D as specifically set forth herein.

    All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D, as amended. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

    Item 1.
    Security and Issuer

    Item 1 of the Schedule 13D is hereby amended and restated as follows:

    The class of equity security to which this statement on Schedule 13D relates is the Common Stock, par value $0.001 per share (the “Common Stock”) of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the “Issuer”), a Delaware corporation. The address of the principal executive offices of the Issuer is 540 Gaither Road, Suite 400, Rockville, Maryland 20850.
     
    Item 3.
    Source and Amount of Funds or Other Consideration

    Item 3 of the Schedule 13D is hereby amended and restated as follows:

    The aggregate purchase price of the securities of the Issuer directly held by the Master Fund and beneficially owned by the Reporting Persons reported herein was $44,671,393.81. The shares of Common Stock held directly by Steven Boyd were received by Mr. Boyd in in-kind distributions from the Master Fund. The securities of the Issuer directly held by the Master Fund and beneficially owned by the Reporting Persons were purchased with the working capital of the Master Fund (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business). Except as disclosed in this Schedule 13D, as amended, all securities of the Issuer reported herein were purchased in open market transactions through a broker.

    Item 4.
    Purpose of Transaction

    Item 4 of the Schedule 13D is supplemented and superseded, as the case may be, as follows:

    On September 14, 2021, the Issuer entered into an underwriting agreement with Jefferies LLC and RBC Capital Markets, LLC as the representatives of the underwriters named therein relating to an underwritten public offering (the “Offering”) of 12,500,000 shares of the Issuer’s Common Stock at a public offering price of $2.20 per share of Common Stock.  The Offering closed on September 17, 2021, and the Reporting Persons on behalf of the Master Fund purchased 5,454,545 shares of Common Stock in the Offering for total consideration of $11,999,999.

    The Reporting Persons purchased the securities of the Issuer for investment in the ordinary course of their investment activities based on the Reporting Persons’ belief that the securities, when purchased, were undervalued and represented an attractive investment opportunity.  The Reporting Persons intend to review their investment in the Issuer on a continuing basis.  Depending on various factors including, without limitation, the Issuer’s financial position, the price levels of the securities of the Issuer, conditions in the securities markets and general economic and industry conditions, the Reporting Persons may in the future take such actions with respect to their investment in the Issuer as they deem appropriate including, without limitation, participating on the Issuer’s Board of Directors (the “Board”), engaging in communications with management and/or the Board, engaging in discussions with stockholders of the Issuer and others about the Issuer and the Reporting Persons’ investment, reshaping the Issuer's corporate strategy, recommending business development transactions, proposing changes to management, operations and the structure of the Board (including the composition of the Board), purchasing additional securities of the Issuer, selling some or all of their securities of the Issuer, engaging in short selling of or any hedging or similar transaction with respect to the securities of the Issuer, or changing their intention with respect to any and all matters referred to in subparagraphs (a) - (j) of Item 4 of Schedule 13D.
     
    Except as otherwise set forth in this Schedule 13D, as amended, the Reporting Persons do not have any present plans or proposals which would relate to, or result in, the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D.  However, subject to market conditions and in compliance with applicable securities laws, the Reporting Persons reserve the right, at a later date, to effect one or more of such changes or transactions in the number of securities of the Issuer they may be deemed to beneficially own in open-market or privately negotiated transactions, on such terms and at such times as the Reporting Persons may deem advisable.

    Item 5.
    Interest in Securities of the Issuer

    Item 5 of the Schedule 13D is hereby amended and restated as follows:

    The information in Item 4 is incorporated herein by reference.

    (a) and (b) Items 7 through 11 and 13 of each of the cover pages of this Schedule 13D are incorporated herein by reference.  The shares of Common Stock reported to be beneficially owned by the Reporting Persons are based on 108,508,951 shares of Common Stock outstanding as of September 17, 2021, based on information in the Issuer’s Prospectus Supplement filed with the SEC on September 15, 2021.  Of the 49,000,000 shares of Common Stock beneficially owned by the Reporting Persons that are directly held by the Master Fund, 4,000,000 of such shares of Common Stock are issuable upon exercise of warrants directly held by the Master Fund and beneficially owned by the Reporting Persons. 

    Armistice Capital is the investment manager of the Master Fund, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund.  Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund.  The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

    (c) The disclosure in Item 4 is incorporated herein by reference.  Except as disclosed in Schedule A hereto or elsewhere in this Schedule 13D, as amended, there have been no transactions in the shares of Common Stock by the Reporting Persons within the past 60 days.  The information in Schedule A is incorporated herein by reference.

    (d) The disclosure in Item 2 is incorporated herein by reference.

    (e) Not applicable.

     
     

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
     
    September 17, 2021
     
     
    (Date)
     
         
         
      Armistice Capital, LLC
     
         
      By:  /s/ Steven Boyd
     
      Name: Steven Boyd
     
     
    Title: Managing Member


     
      Steven Boyd
     
         
      /s/ Steven Boyd
     
     
     

    SCHEDULE A
    TRANSACTIONS
    Except as otherwise disclosed in this Schedule 13D, as amended, the following table sets forth all transactions by the Reporting Persons (on behalf of the Master Fund) with respect to shares of Common Stock effected in the last 60 days, inclusive of any transactions effected through 2:00 p.m., New York City time, on September 17, 2021. Except as otherwise noted, all such transactions were purchases or sales of shares of Common Stock effected in the open market, and the table excludes commissions paid in per share prices.

    NATURE OF TRANSACTION
      
    DATE OF
    TRANSACTION
     
      
    AMOUNT OF
    SECURITIES
     
      
    PRICE PER
    SHARE /
    PREMIUM PER
    OPTION ($)
     
    Purchase of Common Stock
      
     
    08/04/2021
     
      
     
    100,000
     
      
     
    2.6859
     (1) 
    Purchase of Common Stock
      
     
    08/05/2021
     
      
     
    25,000
     
      
     
    2.7718
     
    Purchase of Common Stock
      
     
    08/06/2021
     
      
     
    25,000
     
      
     
    2.8252
     
    Purchase of Common Stock
      
     
    08/16/2021
     
      
     
    30,000
     
      
     
    2.7546
     (2)
    Purchase of Common Stock
      
     
    08/18/2021
     
      
     
    20,000
     
      
     
    2.7775
     
    Purchase of Common Stock
      
     
    09/15/2021
     
      
     
    95,455
     
      
     
    2.2623
     (3)
    Purchase of Common Stock
      
     
    09/16/2021
     
      
     
    150,000
     
      
     
    2.2797
     (4)

    (1) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from $2.6541 to $2.6997. The Reporting Persons undertake to provide the staff of the Securities and Exchange Commission (the “Staff”), upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

    (2) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from $2.7507 to $2.774. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

    (3) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from $2.1461 to $2.3594. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.

    (4) The reported price is a weighted average price. These shares were traded in multiple transactions at prices ranging from $2.1874 to $2.3089. The Reporting Persons undertake to provide the Staff, upon request, full information regarding the number of shares traded at each separate price within the range set forth in this footnote.













































































     
     

    Get the next $CERC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CERC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CERC
    SEC Filings

    See more
    • Cerecor Inc. filed SEC Form 8-K: Leadership Update

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      10/18/21 4:11:35 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:44:34 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 424B5 filed by Cerecor Inc.

      424B5 - Avalo Therapeutics, Inc. (0001534120) (Filer)

      9/15/21 4:41:54 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Leadership Updates

    Live Leadership Updates

    See more
    • Panbela Appoints Industry Veteran, Garry A. Weems, PharmD, as Vice President of Clinical Development & Medical Affairs

      MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced the appointment of Garry A. Weems, PharmD, as its Vice President of Clinical Development and Medical Affairs. Dr. Weems joins Panbela from Cerecor, Inc. (Nasdaq:CERC) where he was Senior Director of Clinical Development. “Panbela has made considerable progress in the last 12-months and is now at a critical juncture as we begin to plan more expansive development of SBP-101,” said Jennifer Simpson, Chief Executive Officer at Panbela. “Garry’s substantial backgroun

      3/15/21 8:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Appoints Schond L. Greenway as Chief Financial Officer

      ROCKVILLE, Md. and CHESTERBROOK, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases, today announced the appointment of Schond L. Greenway as Chief Financial Officer, effective March 1, 2021. Mr. Greenway comes to Cerecor with over 20 years’ experience in investment banking, finance and corporate advisory and investment analysis in the life sciences and financial services industries. Chris Sullivan, who has served as the Company’s Interim Chief Financial Officer for the past year, will continue with the Company as its Chief Accounting

      3/1/21 7:00:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $CERC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CERC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Cantor Fitzgerald initiated coverage on Cerecor with a new price target

      Cantor Fitzgerald initiated coverage of Cerecor with a rating of Overweight and set a new price target of $7.00

      6/4/21 7:42:32 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor upgraded by Maxim Group with a new price target

      Maxim Group upgraded Cerecor from Hold to Buy and set a new price target of $7.00

      4/21/21 9:51:06 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Jefferies initiated coverage on Cerecor with a new price target

      Jefferies initiated coverage of Cerecor with a rating of Buy and set a new price target of $4.00

      4/20/21 7:17:47 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 3 filed by new insider Maher Illya Keith

      3 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/22/21 7:45:39 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Bruhn Suzanne Louise

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:48:25 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Gutry Phil

      4 - Avalo Therapeutics, Inc. (0001534120) (Issuer)

      10/4/21 4:45:42 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      10/14/21 9:01:02 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Cerecor Inc.

      SC 13G - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/21/21 4:51:43 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13D/A filed by Cerecor Inc. (Amendment)

      SC 13D/A - Avalo Therapeutics, Inc. (0001534120) (Subject)

      9/17/21 3:04:41 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care

    $CERC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Avalo Therapeutics, Inc. Announces Corporate Name Change from Cerecor Inc.

      Name change underscores the Company's transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseasesRobust pipeline of six product candidates advancing in development with eight ongoing clinical programsFour therapies with Rare Pediatric Disease Designation with each potentially eligible for a Priority Review Voucher upon approvalMultiple data readouts anticipated in the second half of 2021 WAYNE, Pa. and ROCKVILLE, Md., Aug. 26, 2021 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX), a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significa

      8/26/21 7:30:00 AM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Reports Second Quarter 2021 Financial Results and Provides Business Updates

      Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsAnnounced plans to explore CERC-002 in patients with moderate-to-severe ulcerative colitis refractory to anti-TNF alpha therapiesCompleted $35 million debt financing that extends cash runway and supports multiple clinical catalysts anticipated in the second half of 2021 ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of tre

      8/2/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care
    • Cerecor Announces Drawdown of $10 Million Tranche under its Debt Financing Agreement with Horizon Technology Finance

      ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon"). This second tranche was made available in connection with the Company's successful positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002, an investigational first-in-class fully huma

      8/2/21 7:30:00 AM ET
      $CERC
      $HRZN
      Major Pharmaceuticals
      Health Care
      Finance: Consumer Services
      Finance

    $CERC
    Financials

    Live finance-specific insights

    See more
    • Cerecor Announces Positive Initial Phase 1b Results for CERC-002 in Moderate to Severe Crohn's Disease Patients

      Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatmentsMean reduction in LIGHT levels of approximately 80% compared to baseline signify a dramatic and rapid reduction of LIGHT levels correlating to the pharmacodynamic effect of CERC-002Clinically meaningful endoscopic improvement in 75% (3/4) of subjects, as determined by colonoscopy (SES-CD score)CERC-002 was well tolerated with no drug-related severe adverse eventsCohort 2 (3.0 mg/kg dose) fully enrolled; complete data anticipated in 2H21Promising initial results support expansion to p

      7/26/21 4:01:00 PM ET
      $CERC
      Major Pharmaceuticals
      Health Care